Skip to main content
Clinical Trials/NCT00826033
NCT00826033
Completed
Not Applicable

Fluorine-18-α-Methyltyrosine Positron Emission Tomography to Measure Therapy

Gunma University1 site in 1 countryJanuary 21, 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-Small Cell Lung Cancer
Sponsor
Gunma University
Locations
1
Status
Completed
Last Updated
17 years ago

Overview

Brief Summary

L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for positron emission tomography (PET). The investigators evaluated the value of 18F-FMT PET for the assessment of therapy response in patients with lung cancer as compared with that of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) PET.

The patients with lung cancer underwent PET studies with 18F-FDG and 18F-FMT before and after radio-/chemotherapy. The investigators used the ratio of the SUVmax of the mediastinal (N2) lymph node to the SUVmax of the primary tumor (N/P ratio ). All patients were divided into two groups of N/P ratio<1 and N/P ratio≥1, and the survival time was estimated by Kaplan-Meier method.

Registry
clinicaltrials.gov
Start Date
January 21, 2009
End Date
TBD
Last Updated
17 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • primary lung cancer All patients received first-line chemotherapy

Exclusion Criteria

  • Patients with diabetus mellitus

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials